Americana Partners LLC Acquires 108,399 Shares of Johnson & Johnson (NYSE:JNJ)

Americana Partners LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 141.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 185,084 shares of the company's stock after purchasing an additional 108,399 shares during the period. Johnson & Johnson accounts for approximately 1.1% of Americana Partners LLC's holdings, making the stock its 23rd biggest holding. Americana Partners LLC's holdings in Johnson & Johnson were worth $26,767,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. AMF Tjanstepension AB boosted its stake in Johnson & Johnson by 14.2% during the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company's stock worth $68,985,000 after acquiring an additional 52,997 shares during the last quarter. Alpha Financial Partners LLC bought a new position in shares of Johnson & Johnson during the third quarter worth $209,000. Wealth Group Ltd. acquired a new position in shares of Johnson & Johnson in the 3rd quarter valued at $213,000. Swedbank AB increased its position in shares of Johnson & Johnson by 5.3% in the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company's stock valued at $358,980,000 after buying an additional 111,570 shares in the last quarter. Finally, Foundations Investment Advisors LLC raised its stake in Johnson & Johnson by 21.4% during the 3rd quarter. Foundations Investment Advisors LLC now owns 15,749 shares of the company's stock worth $2,552,000 after buying an additional 2,773 shares during the period. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Up 2.3 %

JNJ traded up $3.71 during trading on Friday, reaching $163.39. 6,875,582 shares of the stock were exchanged, compared to its average volume of 8,893,225. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The stock's 50 day moving average price is $148.61 and its two-hundred day moving average price is $155.89. The stock has a market cap of $393.37 billion, a P/E ratio of 24.54, a price-to-earnings-growth ratio of 2.53 and a beta of 0.52. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the previous year, the company posted $2.29 EPS. Equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.04%. Johnson & Johnson's dividend payout ratio (DPR) is presently 74.59%.

Insider Activity at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Mark A. Weinberger purchased 1,000 shares of the firm's stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on JNJ shares. Barclays increased their price target on Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a report on Tuesday, January 28th. Citigroup lowered their target price on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a research note on Wednesday, December 11th. Wells Fargo & Company reduced their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a report on Thursday, January 23rd. Bank of America dropped their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, January 23rd. Finally, Raymond James reduced their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus target price of $170.67.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.